Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

KIAA1199 expression and hyaluronan degradation colocalize in multiple sclerosis lesions.

Marella M, Jadin L, Keller GA, Sugarman BJ, Frost GI, Shepard HM.

Glycobiology. 2018 Dec 1;28(12):958-967. doi: 10.1093/glycob/cwy064.

2.

Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects.

Rosengren S, Souratha J, Conway D, Muchmore DB, Sugarman BJ.

BioDrugs. 2018 Feb;32(1):83-89. doi: 10.1007/s40259-018-0260-y.

3.

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells.

Marella M, Ouyang J, Zombeck J, Zhao C, Huang L, Connor RJ, Phan KB, Jorge MC, Printz MA, Paladini RD, Gelb AB, Huang Z, Frost GI, Sugarman BJ, Steinman L, Wei G, Shepard HM, Maneval DC, Lapinskas PJ.

Ann Clin Transl Neurol. 2017 Feb 23;4(3):191-211. doi: 10.1002/acn3.393. eCollection 2017 Mar.

4.

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Nov;17(6):1523-4. doi: 10.1208/s12248-015-9822-9. No abstract available.

5.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Sep;17(5):1144-56. doi: 10.1208/s12248-015-9782-0. Epub 2015 May 13. Erratum in: AAPS J. 2015 Nov;17(6):1523-4.

6.

Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.

Dychter SS, Harrigan R, Bahn JD, Printz MA, Sugarman BJ, DeNoia E, Haughey DB, Fellows D, Maneval DC.

Clin Ther. 2014 Feb 1;36(2):211-24. doi: 10.1016/j.clinthera.2013.12.013. Epub 2014 Jan 31.

PMID:
24486335
7.

Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys.

Veneziale RW, Kishnani NS, Nelson J, Resendez JC, Frank DW, Cai XY, Xie L, Cullen C, Frugone CA, Rosenfeld C, Hubbell J, Maxwell SE, Sugarman BJ, Hutchins B, Maneval D, Treinen KA.

Gene Ther. 2012 Jul;19(7):742-51. doi: 10.1038/gt.2011.116. Epub 2011 Sep 8.

PMID:
21900961
8.

Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.

Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI.

Mol Cancer Ther. 2010 Nov;9(11):3052-64. doi: 10.1158/1535-7163.MCT-10-0470. Epub 2010 Oct 26.

9.

Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.

Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI.

Diabetes Technol Ther. 2009 Jun;11(6):345-52. doi: 10.1089/dia.2009.0013.

PMID:
19459762
10.

Tumor growth inhibition by interferon-alpha using PEGylated protein or adenovirus gene transfer with constitutive or regulated expression.

Demers GW, Johnson DE, Machemer T, Looper LD, Batinica A, Beltran JC, Sugarman BJ, Howe JA.

Mol Ther. 2002 Jul;6(1):50-6.

11.

Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles.

Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC.

Toxicol Appl Pharmacol. 2002 Apr 1;180(1):36-42.

PMID:
11922775
12.

Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers.

Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, Sugarman BJ.

Cancer Gene Ther. 2001 Oct;8(10):788-95.

13.

Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.

Atencio IA, Avanzini JB, Johnson D, Neuteboom S, Vaillancourt MT, Nielsen LL, Hajian G, Sutjipto S, Sugarman BJ, Philopena J, McAllister DL, Beltran JC, Nodelman M, Ramachandra M, Wills KN.

Mol Ther. 2001 Jul;4(1):5-12.

14.

Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice.

Ahmed CM, Wills KN, Sugarman BJ, Johnson DE, Ramachandra M, Nagabhushan TL, Howe JA.

J Interferon Cytokine Res. 2001 Jun;21(6):399-408.

PMID:
11440637
15.

In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery.

Ahmed CM, Sugarman BJ, Johnson DE, Bookstein RE, Saha DP, Nagabhushan TL, Wills KN.

Hum Gene Ther. 1999 Jan 1;10(1):77-84.

PMID:
10022532
16.

Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles.

Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S.

Hum Gene Ther. 1997 Mar 1;8(4):453-65.

PMID:
9054520
17.

Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography.

Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P.

Hum Gene Ther. 1995 Nov;6(11):1403-16.

PMID:
8573613
18.

Recombinant human transforming growth factor-beta 1: expression by Chinese hamster ovary cells, isolation, and characterization.

Bourdrel L, Lin CH, Lauren SL, Elmore RH, Sugarman BJ, Hu S, Westcott KR.

Protein Expr Purif. 1993 Apr;4(2):130-40.

PMID:
8471846
20.

Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma.

Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM.

Cancer Res. 1987 Oct 15;47(20):5382-5.

21.

Effects of growth factors on the antiproliferative activity of tumor necrosis factors.

Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM.

Cancer Res. 1987 Feb 1;47(3):780-6.

22.

Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H.

Proc Natl Acad Sci U S A. 1986 Jul;83(14):5233-7.

23.

Tumor necrosis factors: gene structure and biological activities.

Goeddel DV, Aggarwal BB, Gray PW, Leung DW, Nedwin GE, Palladino MA, Patton JS, Pennica D, Shepard HM, Sugarman BJ, et al.

Cold Spring Harb Symp Quant Biol. 1986;51 Pt 1:597-609. No abstract available.

PMID:
3472740
24.

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM.

Science. 1985 Nov 22;230(4728):943-5.

PMID:
3933111
25.

Genomic organization, DNA sequence, and expression of chicken embryonic histone genes.

Sugarman BJ, Dodgson JB, Engel JD.

J Biol Chem. 1983 Jul 25;258(14):9005-16.

26.

A chicken histone H3 gene contains intervening sequences.

Engel JD, Sugarman BJ, Dodgson JB.

Nature. 1982 Jun 3;297(5865):434-6. No abstract available.

PMID:
7078654
27.

Chromosomal arrangement of the chicken beta-type globin genes.

Dolan M, Sugarman BJ, Dodgson JB, Engel JD.

Cell. 1981 Jun;24(3):669-77.

PMID:
7249078
28.

Involvement of menaquinone in the active accumulation of aminoglycosides by Bacillus subtilis.

Taber HW, Sugarman BJ, Halfenger GM.

J Gen Microbiol. 1981 Mar;123(1):143-9.

PMID:
6798165

Supplemental Content

Loading ...
Support Center